{
    "organizations": [],
    "uuid": "9879837b50ef409ed8e8f85e892d8e008b5a4bd3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-personal-genome-diagnostics-entere/brief-personal-genome-diagnostics-enteres-into-a-collaboration-with-five-prime-therapeutics-idUSFWN1RG083",
    "ord_in_thread": 0,
    "title": "BRIEF-Personal Genome Diagnostics enteres into a collaboration with Five Prime Therapeutics",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - Five Prime Therapeutics Inc:\n* ONCOLOGY DRUG CANDIDATE BEMARITUZUMAB * CO INTENDS TO SUBMIT ASSAY FOR REGULATORY APPROVAL, COMMERCIALIZE IN U.S., EUROPE, JAPAN, CHINA, OTHER COUNTRIES\n* FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-03T19:12:00.000+03:00",
    "crawled": "2018-04-04T12:19:12.007+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "five",
        "prime",
        "therapeutic",
        "inc",
        "oncology",
        "drug",
        "candidate",
        "bemarituzumab",
        "co",
        "intends",
        "submit",
        "assay",
        "regulatory",
        "approval",
        "commercialize",
        "europe",
        "japan",
        "china",
        "country",
        "financial",
        "term",
        "agreement",
        "disclosed",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}